Evidence map›Paper›PMID 36540724›Full record

ReviewClinical, cosmetic and investigational dermatology2022

The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside.

Paolo Rovero, Dennis Malvin Hernandez Malgapo, Adele Sparavigna, Ghislaine Beilin, Vincent Wong, Ma Purita Lao

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical, cosmetic and investigational dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Paolo RoveroDepartment of Neurofarba, Section of Pharmaceutical Sciences and Nutraceutics, University of Florence, Florence, Italy.ORCID 0000-0001-9577-5228
Dennis Malvin Hernandez MalgapoSkinsoul Advanced Dermatology and Medical Aesthetics, Quezon City, Metro Manila, Philippines.
Adele SparavignaDERMING S.r.l., Clinical Research and Bioengineering Institute, Milan, Italy.ORCID 0000-0002-7430-1688
Ghislaine BeilinBeilin Consultant, Paris, France.
Vincent WongVindoc Aesthetics Academy, London, UK.ORCID 0000-0002-8825-8705
Ma Purita LaoDepartment of Dermatology, Makati Medical Center, Makati City, Metro Manila, Philippines.
Bioengineering Technology and Systems (Italy) · ITEast Avenue Medical Center · PHMakati Medical Center · PHUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collagen degradation or turnover. SA1-III is a decapeptide (Ac-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln-Lys-NH

Indexed as

aging skinaging wellanti-agingKP1prejuvenationSA1-III

Identifiers

PMID36540724
PMCPMC9760069
OpenAlexW4311319470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.